Company intelligence / Profile preview

Code Invention

Hatfield or greater Philadelphia area, Pennsylvania, United Statescode-invention.com ↗

Ownership: Private
Development stage: Other

Overview

Code Biotherapeutics has demonstrated preclinical proof-of-concept for its proprietary nonviral synthetic DNA delivery platform ("3DNA"), enabling targeted, re-dosable gene therapies for large genes and multiple cell types. Lead programs are advancing toward IND-enabling studies for Duchenne muscular dystrophy and type 1 diabetes. No clinical results reported as of June 2025.

Therapeutic areas: ImmunologyEndocrinologyRare DiseasesNeurology
Modalities: Gene therapySmall interfering RNA (siRNA)Synthetic DNA-based vector (3DNA platform)
Industry: Biotech

Beyond the preview

Go deeper on Code Invention.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Code Invention.

Explore the full profile